-+ 0.00%
-+ 0.00%
-+ 0.00%

BioMarin completes acquisition of Alesta Therapeutics

PUBT·09/01/2026 13:06:16
Listen to the news
BioMarin completes acquisition of Alesta Therapeutics
  • BioMarin completed its acquisition of Alesta Therapeutics on Sept. 1.
  • Deal adds ALE1, an oral small-molecule candidate for hypophosphatasia, strengthening BioMarin’s skeletal conditions portfolio.
  • ALE1 is in an ongoing Phase 1/2a trial in healthy volunteers and adults, evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics.
  • Alesta spun out non-ALE1 assets into a new entity before closing; Alesta now operates as a wholly owned BioMarin subsidiary.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609010905PR_NEWS_USPR_____SF37513) on September 01, 2026, and is solely responsible for the information contained therein.